Fig. 2: Decreased MRPL12 K163 acetylation is linked to poor prognosis in ccRCC.
From: MRPL12 K163 acetylation inhibits ccRCC via driving mitochondrial metabolic reprogramming
A Immunohistochemical (IHC) micrographs showing MRPL12 K163 acetylation levels in paired clinical ccRCC tumor and adjacent normal tissue microarrays (n = 4). Scale bars: 500 μm and 20 μm. B Average H-score quantifying MRPL12 acetylation levels in ccRCC and non-tumor tissue (NTL) samples. C H-score analysis of MRPL12 acetylation levels across 81 paired samples of ccRCC tumors and NTL tissues. D Kaplan–Meier survival curves comparing patient survival using the log-rank test (n = 81). E Analysis of MRPL12 K163 acetylation levels in a cohort of 81 ccRCC patients, showing a significant difference (P < 0.001). F Comparison of H-scores assessing MRPL12 acetylation levels at different disease stages. G Western blot (WB) analysis of MRPL12 acetylation levels in ccRCC tissues (n = 6). H IHC analysis of MRPL12 K163 acetylation levels in paired clinical ccRCC tumor and normal tissues (n = 6). Scale bar: 50 μm. Significance levels: ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
